Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons.

Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE, Riley ED.

AIDS. 2011 May 15;25(8):1113-8. doi: 10.1097/QAD.0b013e3283463f09.

2.
3.

Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.

Pence BW, Miller WC, Gaynes BN, Eron JJ Jr.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):159-66.

PMID:
17146374
4.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

5.

Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men.

Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, Jacobson LP, Strathdee SA.

AIDS. 2002 Mar 29;16(5):775-80.

PMID:
11964534
6.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

7.

Influence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women.

French CE, Tookey PA, Cortina-Borja M, de Ruiter A, Townsend CL, Thorne C.

Antivir Ther. 2013;18(2):183-92. doi: 10.3851/IMP2327. Epub 2012 Aug 22.

PMID:
23475123
8.

The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.

Jevtović Dj, Vanovac V, Veselinović M, Salemović D, Ranin J, Stefanova E.

Biomed Pharmacother. 2009 Sep;63(8):561-5. doi: 10.1016/j.biopha.2008.09.015. Epub 2008 Nov 5.

PMID:
19026516
9.

Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review.

Crepaz N, Hart TA, Marks G.

JAMA. 2004 Jul 14;292(2):224-36.

PMID:
15249572
10.

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S.

AIDS. 2000 Sep 29;14(14):2129-36.

PMID:
11061654
11.

HIV DNA and immune alteration during successful HAART.

Mamadou D, Yu-Huang Z, Xia C, Bo H, Hua-Ying Z, Yan H, Zi C, Qing L, Li-Wen Z, Mei H, Yun-Hai Y, Demba S, Aldebert D, Souleymane M.

Curr HIV Res. 2013 Jun;11(4):255-62.

PMID:
23822818
12.

HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Chander G, Himelhoch S, Fleishman JA, Hellinger J, Gaist P, Moore RD, Gebo KA.

AIDS Care. 2009 May;21(5):655-63. doi: 10.1080/09540120802459762.

13.

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103.

PMID:
15608532
14.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
15.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

16.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
17.

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.

Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.

J Infect Dis. 2004 Nov 15;190(10):1860-8. Epub 2004 Oct 8.

18.

Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.

Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, Gifford A, Liu HH, Nakazono TT, Morton S, Bozzette SA, Shapiro MF, Wenger NS.

J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23.

PMID:
11103041
19.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

20.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

Items per page

Supplemental Content

Write to the Help Desk